Author/Authors :
Shabani، Mahdi نويسنده Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR , , Asgarian Omran، Hossein نويسنده , , Hojjat-Farsangi، Mohammad نويسنده Department of Immunology, School of Public Health, Tehran University of Medical Sciences , , Vossough، Parvaneh نويسنده MAHAK Pediatric Cancer Treatment and Research Center (MPCTRC), Tehran, Iran , , A.Sharifian، Ramazan نويسنده Clinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine, Tehran University of Medical Sciences , , Toughe، Gholam Reza نويسنده Clinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine, Tehran University of Medical Sciences , , Razavi، Seyed Mohsen نويسنده Oncopathology Research Center, Tehran University of Medical Sciences, Tehran, Iran , , Khoshnoodi، Jalal نويسنده Department of Immunology, School of Public Health, Tehran University of Medical Sciences , , Jeddi Tehrani]، Mahmood نويسنده , , Rabbani، Hodjattallah نويسنده Immune and Gene Therapy Laboratory, CCK, Karolinska University Hospital Solna Department of Antigen and Antibody Engineering, Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR , , Shokri، Fazel نويسنده ,
Abstract :
It has recently been shown that ROR1, a member of the receptor tyrosine kinase family, is overexpressed in leukemic B cells of Chronic Lymphocytic Leukemia (CLL) and a subset of Acute Lymphoblastic Leukemia (ALL). In this comparative study the expression profile of ROR1 mRNA was investigated in Iranian patients with CLL and Acute Myelogenous Leukemia (AML) and the results were compared with those previously reported in our Iranian ALL patients. RT-PCR was performed on bone marrow and/or peripheral blood samples of 84 CLL and 12 AML patients. CLL samples were classified into immunoglobulin heavy chain variable region (IGHV) gene mutated (n=55) and unmutated (n=29) and also indolent (n=42) and progressive (n=39) subtypes. ROR1 expression was identified in 94% of our CLL patients, but none of the AML patients expressed ROR1. No significant differences were observed between different CLL subtypes for ROR1 expression. Taken together the present data and our previous results on ROR1 expression in ALL, our findings propose ROR1 as a tumor-associated antigen overexpressed in a large proportion of lymphoid (CLL and ALL), but not myeloid (AML) leukemias. Expression of ROR1 seems to be associated to lineage and differentiation stages of leukemic cells with a potential implication for immunotherapy.
